title: Comparison of enalapril versus captopril on left ventricular function and survival three months after acute myocardial infarction (the "PRACTICAL" study).
abstract: Left ventricular (LV) function and survival can be improved with captopril when initiated later than 24 hours after acute myocardial infarction. Animal studies suggest additional benefits may be obtained with earlier initiation of angiotensin-converting enzyme (ACE) inhibitors. The effects on LV function of captopril and enalapril initiated within 24 hours of myocardial infarction were studied. Two hundred twenty-five patients with acute myocardial infarction were enrolled within 24 hours of the onset of chest pain. They were randomized to receive either captopril 25 mg three times daily, enalapril 5 mg three times daily, or placebo. LV ejection fraction (EF) and volumes were measured by radionuclide ventriculography at baseline during treatment and at 3 months after a 3-day withdrawal from therapy. The ACE inhibitor group had a significant increase in EF (45 +/- 1 to 47 +/- 1%; p = 0.005) and significantly attenuated LV dilatation compared with results in the placebo group (175 +/- 6 to 189 +/- 7 ml in the placebo group vs 168 +/- 4 to 172 +/- 4 ml in the ACE inhibitor group; p = 0.051 for LV end-diastolic volume; and 99 +/- 6 to 108 +/- 7 ml in the placebo group vs 94 +/- 3 to 94 +/- 4 ml; p = 0.026 for LV end-systolic volume). The beneficial effects of ACE inhibitor therapy on LV function were observed irrespective of the degree of initial LV dysfunction and were comparable in both the captopril and enalapril groups.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Cardiology, Princess Margaret Hospital, Christchurch, New Zealand.
authors.forename: S G
authors.initials: SG
authors.lastname: Foy
authors.forename: I G
authors.initials: IG
authors.lastname: Crozier
authors.forename: J G
authors.initials: JG
authors.lastname: Turner
authors.forename: A M
authors.initials: AM
authors.lastname: Richards
authors.forename: C M
authors.initials: CM
authors.lastname: Frampton
authors.forename: M G
authors.initials: MG
authors.lastname: Nicholls
authors.forename: H
authors.initials: H
authors.lastname: Ikram
mesh_terms: D000368:Aged; D000804:Angiotensin II / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002306:Cardiac Volume / Q000187:drug effects; D002423:Cause of Death; D004311:Double-Blind Method; D004361:Drug Tolerance; D004656:Enalapril / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D015637:Gated Blood-Pool Imaging; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D010919:Placebos; D013318:Stroke Volume / Q000187:drug effects; D015996:Survival Rate; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D010919:Placebos; D000804:Angiotensin II; D004656:Enalapril; D002216:Captopril